Apoptosis and Cell Proliferation Capacity in AKR Lymphoma Malignancy Variants

References

• Leoncini L, Del Vecchio M T, Megha T, et al. Correlation between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol 1993; 142: 755–763
   PubMed Web of Science ®Google Scholar
• Gottschalk A R, McShan C L, Merino R, et al. Physiological cell death in B lymphocytes. I. Differential susceptibility of WEHI-231 sublines to anti-Ig induced physiological cell death and lack of correlation with bcl-2 expression. Int Immunol 1994; 6: 121–130
   PubMed Web of Science ®Google Scholar
• Hibner U, Benhamou L E, Haury M, et al. Signaling of programmed cell death induction in WEHI-231 B lymphoma cells. Eur J Immunol 1993; 23: 2821–2825
   PubMed Web of Science ®Google Scholar
• Smets L A, Van den Berg J, Acton D, et al. Bcl-2 expression and mitochondrial activity in leukemic cells with different sensitivity to glucocorticoid-induced apoptosis. Blood 1994; 84: 1613–1619
   PubMed Web of Science ®Google Scholar
• Donin N, Katzenelson D, Ravia J, et al. Apoptosis, cell proliferation and in vivo biological behaviour of primary and metastatic tumor cells of an AKR lymphoma variant. Apoptosis 1997; 2: 214–220
   PubMed Web of Science ®Google Scholar
• Leibovici J. A model for the study of the long duration pathogenesis of cancer and its relevance to therapy. Med Hypoth 1983; 10: 105–112
   PubMed Web of Science ®Google Scholar
• Leibovici J. Serial passage of tumors in mice in the study of tumor progression and testing of antineoplastic drugs. Cancer Res 1984; 44: 1981–1984
   PubMed Web of Science ®Google Scholar
• Leibovici J, Klein O, Wollman Y, et al. Cell membrane fluidity and adriamycin retention in a tumor progression model of AKR lymphoma. Biochim Biophys Acta 1996; 1281: 182–188
   PubMed Web of Science ®Google Scholar
• Klein O, Staroselsky M, Huszar M, et al. Biological behavior and cell properties of new AKR lymphoma malignancy variants. Tissue Cell 1998; 30: 95–103
   PubMed Web of Science ®Google Scholar
• Leibovici J, Zur-Lerman A, Kay S, et al. Differentiation antigens and DNA cytofluorimetric pattern in relation to tumor progression in a murine T lymphoma. XXIst Meeting of the International Society for Oncodevelopmental Biology and Medicine, JerusalemIsrael, 1993; 60
   Google Scholar
• Leibovici J, Klorin G, Huszar M, et al. Sensitivity to thermochemotherapy of AKR lymphoma and B 16 melanoma variants of malignancy. Clin Exp Metast 1990; 8: 33–46
   PubMed Web of Science ®Google Scholar
• Leibovici J, Avichezer D, Gibboa-Garber N. Effect of lectins on tumorigenicity of AKR lymphoma cells of varying malignancy. Anticancer Res 1986; 6: 1411–1416
   PubMed Web of Science ®Google Scholar
• Leibovici J, Michowitz M, Argaman H. Change in the role of the spleen from protective to harmful following tumor progression in the AKR lymphoma. Invasion Metastasis 1990; 10: 289–300
   PubMedGoogle Scholar
• Gout P W, Kang Y J, Buckley D J, et al. Increased cysteine uptake capability associated with malignant progression of Nb2 lymphoma cells. Leukemia 1997; 11: 1329–1337
   PubMed Web of Science ®Google Scholar
• Hao W, Messbarger L, Joshi S S. Immunosuppression by metastatic lymphoma derived altered retroviral gp70 molecule. Leukemia 1997; 11(Suppl 3)202–205
   PubMedGoogle Scholar
• Bortin M H, Truitt R L, Rimm A A. Nonspecific adoptive immuno-therapy of T cell acute lymphoblastic leukemia in AKR mice: a model for treatment of T cell leukemia in man. The Handbook of Cancer Immunology, H Walters. Garland STMP Press, New York 1978; Vol. V: 402–403
   Google Scholar
• Landesman-Bollag E, Channavajhala P L, Cardiff R D, et al. p53 deficiency and missexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. Oncogene 1998; 16: 2965–2974
   PubMed Web of Science ®Google Scholar
• Blyth K, Terry A, O'Hara M, et al. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene 1995; 10: 1717–1723
   PubMed Web of Science ®Google Scholar
• Guidos C J, Williams C J, Grandal I, et al. V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev 1996; 10: 2038–2054
   PubMedGoogle Scholar
• Tamiya S, Etoh K., Suzushima H., et al. Mutation of CD95 (Fas/ Apo-1) gene in adult T-cell leukemia cells. Blood 9 1998; 1: 3935–3942
   Google Scholar
• Silva S, Babonits M, Wiener F, et al. Further studies on chromosome 15 trisomy in murine T-cell lymphomas: mapping of the relevant chromosome segment. Int J Cancer 1988; 41: 738–743
   PubMed Web of Science ®Google Scholar
• Leighton-Grimes H, Chan T O, Zweidler-McKay P A, et al. The Gfi-1 proto-oncoprotein contains a novel transcriptional repressor domain, SNAG and inhibits Gl arrest induced by Interleukin-2 withdrawal. Mol Cell Biol 1996; 16: 6263–6272
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Finger L R, Yunis J, et al. Cloning the chromosome breakpoint of neoplastic B-cells with the t(14:18) chromosome translocation. Science 1984; 226: 1097–1099
   PubMed Web of Science ®Google Scholar
• Cleary M L, Sklar J. Nucleotide sequence of a t(14: 18) chromosomal breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985; 82: 7439–7443
   PubMed Web of Science ®Google Scholar
• Shinto Y, Morimoto M, Katsumata M, et al. Moloney murine leukemia virus infection accelerates lymphomagenesis in Emu-bcl-2 transgenic mice. Oncogene 1995; 11: 1729–1736
   PubMed Web of Science ®Google Scholar
• Reed J C. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1–6
   PubMed Web of Science ®Google Scholar
• Henriksen R, Wilander E, Oberg K. Expression and prognostic significance of bcl-2 in ovarian tumours. Br J Cancer 1995; 72: 1324–1329
   PubMed Web of Science ®Google Scholar
• Lipponen P, Pietilainen T, Kosma V M, et al. Apoptosis suppressing protein bcl-2 is expressed in well differentiated breast carcinomas with favourable prognosis. J Pathol 1995; 177: 49–55
   PubMed Web of Science ®Google Scholar
• Ofner D, Riehemann K, Maier H, et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with rumor stage and patient survival. Br J Cancer 1995; 72: 981–985
   PubMed Web of Science ®Google Scholar
• Thome K C, Radfar A, Rosenberg N. Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells. J Virol 1997; 71: 8149–8156
   PubMed Web of Science ®Google Scholar
• Nguyen P L, Harris N L, Ritz J, et al. Expression of CD95 antigen and bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol 1996; 148: 847–865
   PubMed Web of Science ®Google Scholar
• Vindelov L L, Christensen L J, Nissan N I. Standardisation of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standard. Cytometry 1983; 3: 328–331
   PubMedGoogle Scholar
• Veis D J, Sentman C L, Bach E A, et al. Expression of the bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes. J Immunol 1993; 151: 2546–2554
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Steinberg S M, Nau M M, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7: 171–180
   PubMed Web of Science ®Google Scholar
• Blandino G, Levine A J, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477–485
   PubMed Web of Science ®Google Scholar
• Nigro J M, Baker S J, Preisinger A C, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705–708
   PubMed Web of Science ®Google Scholar
• Leibovici J, Michowitz M, Argaman H, et al. A model for cancer treatment in advanced compared to early cancer. Anticancer Res 1986; 6: 1225–1230
   PubMed Web of Science ®Google Scholar
• McKenna S L, Cotter T G. Functional aspects of apoptosis in hematopoiesis and consequences of failure. Adv Cancer Res 1997; 71: 121–164
   PubMed Web of Science ®Google Scholar
• Dedera D A, Waller E K, LeBrun D P, et al. Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice. Cell 1993; 74: 833–843
   PubMed Web of Science ®Google Scholar
• Steck K D, McDonnell T J, el Naggar A K. Flow cytometric analysis of apoptosis and bcl-2 in human solid neoplasms. Cytometry 1995; 20: 154–161
   PubMedGoogle Scholar
• Kay S, Michowitz M, Donin N, et al. Apoptic cell death and related gene expression in metastatic tumors of AKR lymphomas of varying malignancy. Apoptosis 1999; 429–440
   PubMed Web of Science ®Google Scholar
• Kay S, Donin N, Michowitz M, et al. Release from apoptosis correlates with tumor progression in the AKR lymphoma. Biochim Biophys Acta 2000; 1497: 37–50
   PubMed Web of Science ®Google Scholar
• Messineo C, Hunter Jamerson M, Hunter E, et al. Gene expression by single Reed-Sternberg cells: pathways of apoptosis and activation. Blood 1998; 91: 2443–2451
   PubMed Web of Science ®Google Scholar
• Fujita N, Kato Y, Naito M, et al. A novel anti-Thy-1 (CD90) monoclonal antibody induces apoptosis in mouse malignant Tlymphoma cells in spite of inducing bcl-2 expression. Int J Cancer 1996; 66: 544–550
   PubMed Web of Science ®Google Scholar
• Acton D, Jacobs H, Domen J, et al. Bcl-2 reduces lymphomagenesis in deltaV-TCRbeta transgenic mice. Oncogene 1997; 14: 2497–2501
   PubMed Web of Science ®Google Scholar
• Sullivan G F, Amenta P S, Villanulva J D, et al. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 1998; 4: 1393–1403
   PubMed Web of Science ®Google Scholar
• Sadamori N, Kusano M, Nishino K. A translocation between chromosomes 8 and 14 in a Japanese patient with adult T-cell leukemia. Cancer Genet Cytogenet 1986; 20: 179–180
   PubMed Web of Science ®Google Scholar
• Horie S, Kano M, Higashihara E, et al. Expression of Fas in renal cell carcinoma. Jpn J Clin Oncol 1997; 27: 384–388
   PubMed Web of Science ®Google Scholar
• Baiocchi R A, Khatri V P, Lindemann M J, et al. Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome. Blood 1997; 90: 1737–1746
   PubMed Web of Science ®Google Scholar
• O'Connell J, O'Sullivan G C, Collins J K, et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075–1082
   PubMed Web of Science ®Google Scholar
• Robertson M J, Manley T J, Pichert G, et al. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymph 1995; 17: 51–61
   PubMed Web of Science ®Google Scholar
• Shima Y, Nishimoto N, Ogata A, et al. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 1995; 85: 757–764
   PubMed Web of Science ®Google Scholar
• Hata H, Matsuzaki H, Takeya M, et al. Expression of Fas/APO-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 1995; 86: 1939–1945
   PubMed Web of Science ®Google Scholar
• Yonehara S, Nishimura Y, Kishil S, et al. Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. Int Immunol 1994; 6: 1849–1856
   PubMed Web of Science ®Google Scholar
• Daniel P T, Krammer P H. Activation induces sensitivity toward APO-1 (CD95) mediated apoptosis in human B cells. J Immunol 1994; 152: 5624–5632
   PubMed Web of Science ®Google Scholar
• Ju S T, Cui H, Panka D J, et al. Participation of target Fas protein in apoptosis pathway induced by CD4+ Thl and CD8+ cytotoxic T cells. Proc Natl Acad Sci USA 1994; 92: 4185–4189
   Google Scholar
• Montel A H, Bochan M R, Hobbs J A, et al. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 1995; 166: 236–246
   PubMed Web of Science ®Google Scholar
• Natoli G, Ianni A, Costanzo A, et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995; 11: 1157
   PubMed Web of Science ®Google Scholar
• Cascino I, Papoff G, De-Maria R, et al. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmatic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 1996; 156: 7–13
   Google Scholar
• Wright S C, Zheng H, Zhong J. Tumor cell resistance to apoptosis due to a defect in the activation of sphingomyelinase and the 24 kDa apoptotic protease (AP24). FASEB J 1996; 10: 325–332
   PubMed Web of Science ®Google Scholar
• Itoh N, Tsujimoto Y, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 1993; 151: 621–627
   PubMed Web of Science ®Google Scholar
• Bras A, Martinez A C, Baixeras E. B cell receptor cross-linking prevents Fas-induced cell death by inactivating the IL-1 beta-converting enzyme protease and regulating Bcl-2/Bcl-x expression. J Immunol 1997; 159: 3168–3177
   PubMed Web of Science ®Google Scholar
• Weller M, Malipiero U, Aguzzi A, et al. Protooncogene bcl-2 gene transfer abrogates Fas/APO-I antibody glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995; 95: 2633–2643
   PubMed Web of Science ®Google Scholar
• Jaattela M, Benedict M, Tewari M, et al. Bcl-x and bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 1995; 10: 2297–2305
   PubMed Web of Science ®Google Scholar
• Tamura T, Aoyama N, Saya H, et al. Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene 1995; 11: 1939–1946
   PubMed Web of Science ®Google Scholar
• Albina J E, Martin B A, William L, et al. B cell lymphoma-2 transfected P815 cells resist reactive nitrogen intermediate-mediated macrophage-dependent cytotoxicity. J Immunol 1996; 157: 275–283
   Google Scholar
• Torigoe T, Millan J A, Takayama S, et al. Bcl-2 inhibits T-cellmediated cytolysis of a leukemia cell line. Cancer Res 1994; 54: 4851–4854
   PubMed Web of Science ®Google Scholar
• Schroter M, Lowin B, Borner C, et al. Regulation of Fas (Apo-1 /CD95) and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2. Eur J Immunol 1995; 25: 3509–3513
   PubMed Web of Science ®Google Scholar
• Saxena R K, Collins G D, Chrest J F, et al. Bcl-2 transfection protects Hut78 cell line from different types of cytotoxic effector cells. Immunol Lett 1996; 52: 95–98
   PubMed Web of Science ®Google Scholar
• Hockenbery D M, Oltvai Z N, Yin X M, et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241–251
   PubMed Web of Science ®Google Scholar
• Knight C RL, Rees R C, Platts A, et al. Interleukin-2-activated human effector lymphocytes mediate cytotoxicity by inducing apoptosis in human leukaemia and solid tumor target cells. Immunology 1993; 79: 535–541
   PubMed Web of Science ®Google Scholar
• Yefenof E, Gafanovitch I, Oron E, et al. Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother 1995; 41: 389–396
   PubMed Web of Science ®Google Scholar
• Gillio T S, Cignetti A, Rovera G, et al. Retroviral vector-mediated transfer of the tumor necrosis factor alpha gene into human cancer cells restores an apoptotic cell death program and induces a bystander-killing effect. Blood 1996; 87: 2486–2495
   PubMed Web of Science ®Google Scholar
• Klein O, Savion N, Staroselsky A, et al. Cellular functions related to metastasis differing between low- and high-malignancy variants of AKR lymphoma. Pathobiology 1992; 60: 157–162
   PubMed Web of Science ®Google Scholar
• Klein O, Staroselsky A, Savion N, et al. Metastasis associated cell functions in AKR lymphoma malignancy variants. Invasion Metastasis 1996; 15: 211–221
   Google Scholar